Browsing Tag
pharma R&D
2 posts
Anthem Biosciences (NSE: ANTHEM) Q2 FY26 results: Can strong CRDMO tailwinds keep driving profitability?
Anthem Biosciences Q2 FY26 results reveal strong CRDMO-led growth and 44.5% EBITDA margins. Find out what’s driving investor sentiment and what’s next.
Why AI–CRDMO partnerships are gaining ground in early-stage drug discovery pipelines
AI–CRDMO collaborations are changing how drugs are discovered and validated. See why they’re attracting biotech startups and pharma innovators alike.